Intended Use

“MagQu” α-Synuclein Control Solution is used as a standard control for “MagQu” α-Synuclein IMR Reagent (MF-ASC-006B).

Introduction

α-Synuclein (SNCA) is a presynaptic neuronal protein and is abundant in the human brain. α-Synuclein aggregates to form insoluble fibrils in pathological conditions characterized by Lewy bodies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). These disorders are known as synucleinopathies. α-Synuclein is the primary structural component of Lewy body fibrils. Occasionally, Lewy bodies contain tau protein; however, α-Synuclein and tau constitute two distinctive subsets of filaments in the same inclusion bodies. α-Synuclein pathology is also found in both sporadic and familial cases with Alzheimer's disease.^{1, 2, 3}

Principle of Test

α-Synuclein Control Solution is used as a standard control for “MagQu” α-Synuclein IMR Reagent (MF-ASC-006B). The antibody conjugated on the surface of Fe₃O₄ magnetic particles (~ 50 nm) could bind with α-Synuclein and form clusters. With the increase of cluster, the signal of ac susceptibility ( χ_ac ) will decrease in the applied ac magnetic field. That is the principle of Immuno Magnetic Reduction (IMR). By measuring the reduction of χ_ac , we can quantify the α-Synuclein in the sample easily and accurately.^4,5

References

1. Anzari Atik, Tessandra Stewart, Jing Zhang, “Alpha-synuclein as a biomarker for Parkinson's disease”, Brain Pathology, Volume 26, Issue 3, pages 410–418, May 2016
2. Oskar Hansson, Sara Hall, Annika Öhrfelt, Henrik Zetterberg, Kaj Blennow, Lennart Minthon, Katarina Nägga, Elisabet Londos, Shiji Varghese, Nour K Majbour, Abdulmonem Al-Hayani, Omar MA El-Agna, “Levels of cerebrospinal fluid α-Synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease”, Hansson et al. Alzheimer's Research & Therapy, 2014, 6:25.
3. D.J. Irwin, V.M.Y. Lee, and J.Q. Trojanowski, “Parkinson's disease dementia convergence of α-Synuclein, tau and amyloid-β pathologies”, Nat Rev Neurosci., 14, 626–636, 2013.
4. C.Y. Hong, C.C. Wu, Y.C. Chiu, S.Y. Yang, H.E. Horng, H.C. Yang, “Magnetic susceptibility reduction method for magnetically labeled immunoassay”, Appl. Phys. Lett. , 88, 212512-1–212512- 3, 2006.
5. C.C. Yang, S.Y. Yang, C. S. Ho, et al, ”Development of antibody functionalized magnetic nanoparticles for the immunoassay of carcinoembryonic antigen: a feasibility study for clinical use.”, Journal of Nanobiotechnology, 2014, 12:44.